Australia - engelsk - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - mesalazine, quantity: 1.6 g - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate type a; hypromellose; colloidal anhydrous silica; magnesium stearate; macrogol 6000; methacrylic acid copolymer; triethyl citrate; glyceryl monostearate; polysorbate 80; sodium hydroxide; maize starch; iron oxide red; iron oxide yellow; monobasic potassium phosphate - asacol is indicated for the treatment of mild to moderate ulcerative colitis and maintenance of remission in adults.

Serbia - serbisk - Агенција за лекове и медицинска средства Србије (Agencija za lekove i medicins)

pontus pharma d.o.o. beograd - месалазин - gastrorezistentna tableta - 400mg

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - mesalazine, quantity: 800 mg - tablet, enteric coated - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; magnesium stearate; purified talc; povidone; methacrylic acid copolymer; triethyl citrate; iron oxide yellow; iron oxide red; macrogol 6000 - for the treatment of mild to moderate ulcerative colitis and maintenance of remission in adults.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - mesalazine, quantity: 400 mg - tablet, enteric coated - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; magnesium stearate; purified talc; povidone; methacrylic acid copolymer; triethyl citrate; iron oxide yellow; iron oxide red; macrogol 6000 - for the treatment of mild to moderate ulcerative colitis and maintenance of remission in adults.

USA - engelsk - NLM (National Library of Medicine)

cardinal health - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) - mesalamine 400 mg - asacol tablets are indicated for the treatment of mildly to moderately active ulcerative colitis and for the maintenance of remission of ulcerative colitis. asacol tablets are contraindicated in patients with hypersensitivity to salicylates or to any of the components of the asacol tablet. abuse: none reported. dependency: drug dependence has not been reported with chronic administration of mesalamine.

USA - engelsk - NLM (National Library of Medicine)

state of florida doh central pharmacy - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) - mesalamine 400 mg - asacol tablets are indicated for the treatment of mildly to moderately active ulcerative colitis and for the maintenance of remission of ulcerative colitis. asacol tablets are contraindicated in patients with hypersensitivity to salicylates or to any of the components of the asacol tablet. none reported. drug dependence has not been reported with chronic administration of mesalamine.

USA - engelsk - NLM (National Library of Medicine)

state of florida doh central pharmacy - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) - mesalamine 400 mg - asacol tablets are indicated for the treatment of mildly to moderately active ulcerative colitis and for the maintenance of remission of ulcerative colitis. asacol tablets are contraindicated in patients with hypersensitivity to salicylates or to any of the components of the asacol tablet. abuse: none reported. dependency: drug dependence has not been reported with chronic administration of mesalamine.

USA - engelsk - NLM (National Library of Medicine)

allergan, inc. - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) - mesalamine 800 mg - asacol hd is indicated for the treatment of moderately active ulcerative colitis in adults. limitations of use : safety and effectiveness of asacol hd beyond 6 weeks have not been established. asacol hd is contraindicated in patients with known or suspected hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of asacol hd [see warnings and precautions (5.3) , adverse reactions (6.2) , and description (11) ]. risk summary limited published data on mesalamine use in pregnant women are insufficient to inform a drug-associated risk. no fetal harm was observed in animal reproduction studies of mesalamine in rats and rabbits at oral doses approximately 0.97 times (rat) and 1.95 times (rabbit) the recommended human dose ( see data ) . the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2

Serbia - serbisk - Агенција за лекове и медицинска средства Србије (Agencija za lekove i medicins)

predstavniŠtvo sandoz pharmaceuticals d.d. beograd - месалазин - gastrorezistentna tableta - 800mg

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - mesalazine 400mg - enteric coated tablet - 400 mg - active: mesalazine 400mg excipient: iron oxide red iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate methacrylic acid copolymer povidone purified talc   sodium starch glycolate triethyl citrate - induction of remission of mild to moderate episodes of ulcerative colitis. maintenance of remission of ulcerative colitis.